An intravenous antibody-drug conjugate targeting delta-like protein 3 (DLL3) for third-line treatment of small cell lung cancer.
If you have a Hayes login, click here to view the full report on the Knowledge Center.
An intravenous antibody-drug conjugate targeting delta-like protein 3 (DLL3) for third-line treatment of small cell lung cancer.
If you have a Hayes login, click here to view the full report on the Knowledge Center.